.jpg)
Digital Archive
This story is part of our historical records. While preserved for reference, some details and facts may have evolved since its original publication 6 months ago.
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days
S
Sangri Today Spotlight
BREAKING
Sangri Today
4 years ago
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days
Full Story: https://www.sangritoday.com/spotlight/polypid-announces-recommendation-by-data-safety-monitoring-board-to-conclude-enrollment-of-phase-3-shield-i-trial-of-d-plex₁₀₀-at-the-minimum-number-of-patients-targeted-following-unblinded-interim-efficacy-analysis
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days
history
This is an archived post. The information provided may be outdated.
